In 2017, 46 new medicines were approved by the FDA – the highest number of approvals in 21 years.1 Scott Gottlieb, who was sworn in as FDA Commissioner in May 2017,2 has made use of policy changes put into effect during recent years to accelerate the approval process.1 This issue of The Rx Consultant focuses on new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: venous thromboembolism prophylaxis, atopic dermatitis, hepatitis C infection, psoriasis, HER2-positive breast cancer, Parkinson disease, Huntington disease, tardive dyskinesia, and bacterial vaginosis. Two new glaucoma medications are summarized in the online appendix. Dosing, drug interactions, and pronunciation guides are shown in Table 1. Brief descriptions of 14 additional new drugs are included in Table 2...
This CE activity is a monograph (PDF file).
- Pharmacy Technicians
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- For each of the drugs reviewed in the issue:
A. State the generic name, brand name, FDA approved indication(s), and usual dose.
B. Describe common side effects, serious side effects, and significant drug interactions.
- For drugs listed in Table 2:
C. State the generic name, brand name, FDA approved indication(s), and usual dose.
James Chan, Pharm.D., PhD
Brief Bio : James Chan, PharmD, PhD, Pharmacy Quality and Outcomes Coordinator, Kaiser Permanente, Oakland, CA and Associate Clinical Professor, School of Pharmacy, University of California, San Francisco, CA.
Pamela Mausner, MD
Brief Bio : Pamela Mausner, MD; Medical Writer/Editor and Healthcare Advocate; and Associate Editor, The Rx Consultant.
Release Date: Mar 22, 2018
Credit Expiration Date: Mar 22, 2021